ETON PHARMACEUTICALS INC

Opaleye Management’s July 14 sale of 15k Eton Pharma shares shows tactical profit‑taking amid a sharp rally, hinting at possible short‑term pullback.

Opaleye Management’s July sell‑off of Eton Pharmaceuticals shares is a calculated risk‑management move, not a warning, offering investors insight into strategic rebalancing and insider confidence.

Explore Eton Pharma’s insider sales: CEO Sean Brynjelsen’s tactical off‑load and its impact on the stock’s growth outlook and investor strategy.

Insider buying signals at Eton Pharmaceuticals: RIEDEL’s recent stake build shows confidence amid a 12‑week dip, hinting at future upside from clinical milestones.